EP3311168
NOVEL TNF STRUCTURE FOR USE IN THERAPY
:
EP einkaleyfi: Þýðing ekki lögð inn:
22.10.2015:
10.5.2023:
15784067.9
:
21.10.2035
:
NOVEL TNF STRUCTURE FOR USE IN THERAPY
22.10.2015
10.5.2023
:
UCB Biopharma SRL:
Allée de la Recherche 60, 1070 Brussels, BE
:
O'CONNELL, James Philip:
Slough Berkshire SL1 3WE, GB
:
PORTER, John Robert:
Slough Berkshire SL1 3WE, GB
:
LAWSON, Alastair:
Slough Berkshire SL1 3WE, GB
:
KROEPLIEN, Boris:
Slough Berkshire SL1 3WE, GB
:
RAPECKI, Stephen Edward:
Slough Berkshire SL1 3WE, GB
:
NORMAN, Timothy John:
Slough Berkshire SL1 3WE, GB
:
WARRELLOW, Graham John:
Slough Berkshire SL1 3WE, GB
:
ARAKAKI, Tracy Lynn:
Slough Berkshire SL1 3WE, GB
:
BURGIN, Alex Buntin:
Slough Berkshire SL1 3WE, GB
:
PITT, William Ross:
Slough Berkshire SL1 3WE, GB
:
CALMIANO, Mark Daniel:
Slough Berkshire SL1 3WE, GB
:
SCHUBERT, David Andreas:
Slough Berkshire SL1 3WE, GB
:
LIGHTWOOD, Daniel John:
Slough Berkshire SL1 3WE, GB
:
WOOTTON, Rebecca Jayne:
Slough Berkshire SL1 3WE, GB
:
201510758:
18.6.2015:
GB
:
EP2015074491:
22.10.2015
:
G01N 33/68, C07K 14/705, C07K 14/525, C07D 401/14, C07D 471/00